Unicycive Therapeutics Faces Securities Class Action Lawsuit

What Happened Unicycive Therapeutics, Inc. (UNCY) disclosed in a Form 8-K (Item 8.01) filed September 28, 2026 that a securities class action complaint was filed on September 3, 2026 in the U.S. District Court for the Northern District of California. The suit names the company and certain of its officers and alleges violations of federal securities laws related to public statements about the company’s new drug application (NDA) for oxylanthanum carbonate, a phosphate binder intended to treat hyperphosphatemia in chronic kidney disease patients on dialysis. The company stated it believes the claims are meritless and intends to vigorously defend the lawsuit.

Key Details

• Lawsuit filed: September 3, 2026, in U.S. District Court, Northern District of California.
• Parties: Unicycive Therapeutics, Inc. and certain officers named as defendants.
• Subject matter: Alleged securities-law violations tied to public statements about the NDA for oxylanthanum carbonate (phosphate binder for hyperphosphatemia in dialysis patients).
• Company stance: Declared the claims meritless and that it will vigorously defend; no damages amount, settlement, or financial impact disclosed in the 8-K.

Why It Matters A securities class action can lead to legal costs, management distraction, and potential financial exposure if resolved adversely; these cases can also influence investor sentiment and share price volatility. At this early stage the company has not disclosed any financial reserve or estimated impact, so investors should monitor court filings and company updates for developments (e.g., motions, lead plaintiff designation, settlement talks) that could affect UNCY’s financials or outlook.